Table 4 Treatment-emergent adverse events (aes) (all grades) reported by ≥20% of subjects in a treatment stratum
Preferred term, n (%) | TAC + Bevacizumab (n = 92) | TCH + Bevacizumab (n = 34) | Total (N = 126) |
|---|---|---|---|
Subjects with at least one AE | 92 (100.0) | 34 (100.0) | 126 (100.0) |
Fatigue | 79 (85.9) | 30 (88.2) | 109 (86.5) |
Nausea | 75 (81.5) | 28 (82.4) | 103 (81.7) |
Alopecia | 73 (79.3) | 28 (82.4) | 101 (80.2) |
Diarrhea | 57 (62.0) | 24 (70.6) | 81 (64.3) |
Arthralgia | 47 (51.1) | 20 (58.8) | 67 (53.2) |
Constipation | 46 (50.0) | 18 (52.9) | 64 (50.8) |
Epistaxis | 43 (46.7) | 18 (52.9) | 61 (48.4) |
Headache | 40 (43.5) | 17 (50.0) | 57 (45.2) |
Insomnia | 39 (42.4) | 16 (47.1) | 55 (43.7) |
Vomiting | 39 (42.4) | 12 (35.3) | 51 (40.5) |
Decreased appetite | 38 (41.3) | 10 (29.4) | 48 (38.1) |
Hot flush | 33 (35.9) | 15 (44.1) | 48 (38.1) |
Anemia | 33 (35.9) | 13 (38.2) | 46 (36.5) |
Lacrimation increased | 31 (33.7) | 14 (41.2) | 45 (35.7) |
Neutropenia | 39 (42.4) | 5 (14.7) | 44 (34.9) |
Dysgeusia | 25 (27.2) | 17 (50.0) | 42 (33.3) |
Stomatitis | 30 (32.6) | 12 (35.3) | 42 (33.3) |
Cough | 30 (32.6) | 8 (23.5) | 38 (30.2) |
Thrombocytopenia | 25 (27.2) | 13 (38.2) | 38 (30.2) |
Dyspepsia | 24 (26.1) | 13 (38.2) | 37 (29.4) |
Hypertension | 26 (28.3) | 11 (32.4) | 37 (29.4) |
Bone pain | 31 (33.7) | 5 (14.7) | 36 (28.6) |
Dyspnea | 23 (25.0) | 7 (20.6) | 30 (23.8) |
Oropharyngeal pain | 17 (18.5) | 10 (29.4) | 27 (21.4) |
Depression | 19 (20.7) | 6 (17.6) | 25 (19.8) |
Leukopenia | 19 (20.7) | 5 (14.7) | 24 (19.0) |
Mucosal inflammation | 16 (17.4) | 7 (20.6) | 23 (18.3) |
Pain in extremity | 20 (21.7) | 3 (8.8) | 23 (18.3) |
Rash | 14 (15.2) | 9 (26.5) | 23 (18.3) |
Back pain | 14 (15.2) | 7 (20.6) | 21 (16.7) |
Musculoskeletal pain | 13 (14.1) | 8 (23.5) | 21 (16.7) |
Edema peripheral | 11 (12.0) | 7 (20.6) | 18 (14.3) |
Sinusitis | 11 (12.0) | 7 (20.6) | 18 (14.3) |
UTI | 10 (10.9) | 8 (23.5) | 18 (14.3) |
Nail disorder | 9 (9.8) | 8 (23.5) | 17 (13.5) |
Dry skin | 8 (8.7) | 8 (23.5) | 16 (12.7) |
Alanine aminotransferase increased | 3 (3.3) | 7 (20.6) | 10 (7.9) |